See the DrugPatentWatch profile for fintepla

Fintepla (fenfluramine) is a medication used to treat seizures associated with Dravet syndrome, a rare and severe form of epilepsy. According to the drug's manufacturer, Zogenix, the list price of Fintepla is $37,500 per year for the maximum recommended dosage [1].

Comparing Fintepla's cost to other anti-seizure medications, we find a range of prices for both brand-name and generic drugs. For instance, Epidiolex, another FDA-approved treatment for Dravet syndrome, has a list price of $34,000 per year [2]. On the other hand, generic options like valproate sodium can cost as little as $500 per year [3].

It is important to note that these list prices do not necessarily reflect the out-of-pocket costs for patients, as insurance coverage, discounts, and other factors can significantly impact the final cost. Additionally, the rarity and specificity of Dravet syndrome treatments can affect pricing and accessibility.

Sources:

1. [Fintepla (fenfluramine) oral solution, for oral use - prescribing information, dosage, side effects, and drug interactions - Zogenix](https://www.finteplahcp.com/pdf/fintepla-pi.pdf)
2. [Epidiolex (cannabidiol) oral solution - prescribing information, dosage, side effects, and drug interactions - Greenwich Biosciences](https://www.epidiolex.com/sites/default/files/prescribing-information.pdf)
3. [Drugs.com - Valproate Sodium](https://www.drugs.com/mtm/valproate-sodium.html)
4. [DrugPatentWatch.com - Fintepla (fenfluramine) - Patent Expiration & Generic Entry](https://www.drugpatentwatch.com/drugs/fintepla)